These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35749758)

  • 1. Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.
    Landry I; Hall N; Aluri J; Filippov G; Reyderman L; Setnik B; Henningfield J; Moline M
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):365-373. PubMed ID: 35749758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users.
    Landry I; Hall N; Alur J; Filippov G; Reyderman L; Setnik B; Henningfield J; Moline M
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):374-382. PubMed ID: 35748777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
    Gotfried MH; Auerbach SH; Dang-Vu TT; Mishima K; Kumar D; Moline M; Malhotra M
    Drugs Aging; 2024 Sep; 41(9):741-752. PubMed ID: 39120786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
    Ufer M; Kelsh D; Schoedel KA; Dingemanse J
    Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
    Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
    J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.
    Murphy P; Kumar D; Zammit G; Rosenberg R; Moline M
    J Clin Sleep Med; 2020 May; 16(5):765-773. PubMed ID: 32022664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act.
    Moline M; Asakura S; Beuckman C; Landry I; Setnik B; Ashworth J; Henningfield JE
    Psychopharmacology (Berl); 2023 Apr; 240(4):699-711. PubMed ID: 36749354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
    Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
    CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea.
    Cheng JY; Lorch D; Lowe AD; Uchimura N; Hall N; Shah D; Moline M
    J Clin Sleep Med; 2024 Jan; 20(1):57-65. PubMed ID: 37677076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.
    Levy-Cooperman N; Schoedel KA; Chakraborty B; Blum D; Cheng H
    Epilepsy Behav; 2016 Aug; 61():63-71. PubMed ID: 27315134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant.
    Asakura S; Shiotani M; Gauvin DV; Fujiwara A; Ueno T; Bower N; Beuckmann CT; Moline M
    Regul Toxicol Pharmacol; 2021 Dec; 127():105053. PubMed ID: 34619288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transitioning insomnia patients from zolpidem to lemborexant: A multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy.
    Ahmad M; Kelly J; Montano CB; Kumar D; Perdomo C; Malhotra M; Amchin J; Moline M
    Sleep Med X; 2024 Dec; 7():100098. PubMed ID: 38312371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study.
    Ozone M; Hirota S; Ariyoshi Y; Hayashida K; Ikegami A; Habukawa M; Ohshima H; Harada D; Hiejima H; Kotorii N; Murotani K; Taninaga T; Uchimura N
    Adv Ther; 2024 Apr; 41(4):1728-1745. PubMed ID: 38460107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
    Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
    Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lemborexant in midlife women with insomnia disorder.
    Terauchi M; Cheng JY; Yardley J; Pinner K; Moline M; Malhotra M; Inabe K; Nishida M; Pappadopulos E
    Menopause; 2023 Aug; 30(8):839-848. PubMed ID: 37339396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
    Keks NA; Hope J
    Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L; Juday T; Frech F; Atkins N
    J Clin Psychiatry; 2021 Jun; 82():. PubMed ID: 34077032
    [No Abstract]   [Full Text] [Related]  

  • 19. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
    Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
    Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
    Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
    Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.